Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 KINASE DOMAIN MUTATION
ERBB2 KINASE DOMAIN MUTATION - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/959
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/413
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Afatinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22325357
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Afatinib | Sensitivity | true |